The Clorox Company (NYSE:CLX) Shares Purchased by Canvas Wealth Advisors LLC

Canvas Wealth Advisors LLC lifted its stake in The Clorox Company (NYSE:CLX - Free Report) by 178.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,171 shares of the company's stock after buying an additional 6,513 shares during the period. Canvas Wealth Advisors LLC's holdings in Clorox were worth $1,445,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of CLX. Norges Bank purchased a new stake in Clorox in the fourth quarter valued at approximately $259,041,000. FMR LLC raised its position in Clorox by 75.4% in the 4th quarter. FMR LLC now owns 1,361,758 shares of the company's stock valued at $221,163,000 after purchasing an additional 585,526 shares during the last quarter. Marshall Wace LLP boosted its stake in Clorox by 549.8% during the 4th quarter. Marshall Wace LLP now owns 542,726 shares of the company's stock worth $88,144,000 after purchasing an additional 459,203 shares during the period. ExodusPoint Capital Management LP boosted its stake in Clorox by 187.9% during the 4th quarter. ExodusPoint Capital Management LP now owns 698,900 shares of the company's stock worth $113,508,000 after purchasing an additional 456,114 shares during the period. Finally, Man Group plc grew its position in Clorox by 154.6% during the 4th quarter. Man Group plc now owns 570,503 shares of the company's stock worth $92,655,000 after purchasing an additional 346,449 shares during the last quarter. 78.53% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Pierre R. Breber bought 4,000 shares of the firm's stock in a transaction on Wednesday, May 7th. The shares were bought at an average cost of $136.57 per share, for a total transaction of $546,280.00. Following the completion of the transaction, the director now owns 4,000 shares in the company, valued at $546,280. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.57% of the stock is currently owned by company insiders.

Clorox Price Performance

CLX stock traded up $0.90 on Monday, reaching $120.04. 1,497,792 shares of the company's stock were exchanged, compared to its average volume of 1,387,751. The stock has a fifty day moving average of $131.21 and a 200-day moving average of $145.00. The firm has a market cap of $14.80 billion, a PE ratio of 21.55, a P/E/G ratio of 2.70 and a beta of 0.54. The company has a quick ratio of 0.44, a current ratio of 0.74 and a debt-to-equity ratio of 13.07. The Clorox Company has a twelve month low of $117.35 and a twelve month high of $171.37.

Clorox (NYSE:CLX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported $1.45 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by ($0.12). The company had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.74 billion. Clorox had a return on equity of 324.23% and a net margin of 9.89%. The business's revenue for the quarter was down 8.0% compared to the same quarter last year. During the same period last year, the company earned $1.71 earnings per share. As a group, equities analysts predict that The Clorox Company will post 7.15 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on CLX shares. Evercore ISI set a $140.00 target price on shares of Clorox and gave the company an "underperform" rating in a report on Tuesday, May 6th. Barclays reduced their price objective on Clorox from $134.00 to $129.00 and set an "underweight" rating for the company in a research note on Wednesday, May 7th. Morgan Stanley lowered their target price on Clorox from $165.00 to $150.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. Wells Fargo & Company dropped their target price on Clorox from $145.00 to $142.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. Finally, Jefferies Financial Group cut their price target on Clorox from $167.00 to $145.00 and set a "buy" rating for the company in a research note on Thursday. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $149.50.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.